gene expression

This Week in Nature

In Nature this week: trove of data from the Genotype Tissue Expression consortium, and more.

Investigators compared RNA sequence data in heart samples from individuals with dilated cardiomyopathy and samples from healthy transplant donor hearts.

Gene expression may offer clues to antibody activity after flu vaccination in individuals under 35, according to expression data for hundreds of individuals. 

NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.

A new analysis hints that adenocarcinomas or squamous cell carcinomas may have certain overlapping expression patterns, regardless of the tissue of origin.

Researchers led by Jennifer Doudna found that the architecture of the Cas1-Cas2 integrase contributes to bacterial adaptive immunity.

Examining more than half of its genome, researchers found the parasite's success is due to stripping its genome down to essential genes.

Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.

A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic. 

The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.